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Cannabinoid 1 receptor (CB1R) inverse agonists are
emerging as a potential obesity therapy. However,
the physiological mechanisms by which these agents
modulate human energy balance are incompletely
elucidated. Here, we describe a comprehensive clin-
ical research study of taranabant, a structurally novel
acyclic CB1R inverse agonist. Positron emission to-
mography imaging using the selective CB1R tracer
[18F]MK-9470 confirmed central nervous system
receptor occupancy levels (10%–40%) associated
with energy balance/weight-loss effects in animals.
In a 12-week weight-loss study, taranabant induced
statistically significant weight loss compared to pla-
cebo in obese subjects over the entire range of eval-
uated doses (0.5, 2, 4, and 6 mg once per day) (p <
0.001). Taranabant treatment was associated with
dose-related increased incidence of clinical adverse
events, including mild to moderate gastrointestinal
and psychiatric effects. Mechanism-of-action stud-
ies suggest that engagement of the CB1R by tarana-
bant leads to weight loss by reducing food intake and
increasing energy expenditure and fat oxidation.
INTRODUCTION
The appetitive effects of Cannabis sativa (marijuana) have been
known for millennia from its medicinal and recreational use
68 Cell Metabolism 7, 68–78, January 2008 ª2008 Elsevier Inc.(Nicoll and Alger, 2004; Di Marzo et al., 2004). However, a mod-
ern-day understanding of the psychoactive ingredients of
marijuana has led to the recognition that endogenous cannabi-
noids (endocannabinoids) are important regulators of energy
balance (Di Marzo et al., 2001, 2004; Nicoll and Alger, 2004;
De Petrocellis et al., 2004; Osei-Hyiaman et al., 2006). Endocan-
nabinoids are believed to promote appetite and food intake by
activating cannabinoid 1 receptors (CB1Rs) expressed in hypo-
thalamic centers that regulate energy balance, limbic system
reward pathways, and other cortical and subcortical regions
(Di Marzo et al., 2004; Gardner, 2005; Osei-Hyiaman et al.,
2006). In addition, the CB1R is abundantly expressed throughout
the central nervous system (CNS) (Howlett et al., 2002), and
CB1R mRNA has also been detected in several peripheral tis-
sues (Cota et al., 2003; Bensaid et al., 2003; Osei-Hyiaman
et al., 2005a; Matias et al., 2006).
In the CNS, endocannabinoids function as retrograde mes-
sengers, which modulate stimulatory and inhibitory neurotrans-
mitters (e.g., glutamate and g-aminobutyric acid) (Christie and
Vaughan, 2001; Diana and Marty, 2004). Through this mecha-
nism or via as yet undefined direct or indirect effects, endocan-
nabinoids play an important role in the complex process of
consummatory behavior. Fasting increases levels of endocanna-
binoids in the hypothalamus and limbic forebrain (Kirkham et al.,
2002), and either their peripheral administration (Williams and
Kirkham, 1999; Hao et al., 2000) or microinjection into specific
hypothalamic (Jamshidi and Taylor, 2001) or limbic forebrain
(Kirkham et al., 2002) sites stimulates feeding in rodents. Endo-
cannabinoids have also been implicated in interacting with
multiple well-recognized energy homeostatic pathways, includ-
ing the leptin (Di Marzo et al., 2001), proopiomelanocortin (Verty
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et al., 2004), and melanin-concentrating hormone (Cota et al.,
2003; Jo et al., 2005) pathways, among others (Cota et al., 2003;
Chen et al., 2004; Burdyga et al., 2004; Verty et al., 2004b; Osei-
Hyiaman et al., 2005b).
However, several observations suggest that a decrease in
central orexigenic drive cannot fully account for the antiobesity
effects of CB1R inverse agonists. In rodent studies, acute treat-
ment with the CB1R inverse agonists rimonabant or taranabant
acutely causes a dose-dependent reduction in food intake,
whereas longer-term treatment shows a less robust dose re-
sponse in daily food intake, even though chronic weight loss is
clearly dose dependent (Ravinet Trillou et al., 2003; Fong et al.,
2007). Moreover, genetically obese ob/ob mice treated daily
for 7 days with rimonabant have been observed to have in-
creased oxygen consumption (Liu et al., 2005). However, it is
not uncommon for rodent results to lack correlation with human
observations. For example, rodents have brown fat, which is
a recognized target for increasing oxygen consumption and
energy expenditure (Jbilo et al., 2005). In contrast, brown fat is
poorly developed in humans, and this particular mechanism
would be unavailable.
Taranabant is a structurally novel, highly selective, potent,
orally bioavailable acyclic CB1R inverse agonist (Lin et al.,
2006) that has been demonstrated to cause weight loss in rodent
studies (Fong et al., 2007) at trough CNS receptor occupancy
levels above 30%. The aim of the present series of studies was
to extend these observations to humans, with the specific goal
of testing the hypothesis that taranabant at CNS receptor occu-
pancy levels comparable to those observed in animals sup-
presses food intake, stimulates energy expenditure, and
promotes negative energy balance with weight loss over
a 12-week proof-of-concept period. As part of our taranabant
safety and tolerability monitoring, we evaluated potential ad-
verse events associated with peripheral (i.e., gastrointestinal)
and central (i.e., psychiatric) CB1R distribution. Studies were
completed between 2004 and 2006. Study participants were
not enrolled in more than one study.
RESULTS
Brain CB1R Occupancy Study
Autoradiography studies in rodents have demonstrated that
chronic weight loss is associated with at least 25%–30%
CB1R occupancy at 24 hr (Fong et al., 2007). A positron emission
tomography (PET) study was performed at a single study center
(Katholieke Universiteit Leuven; Leuven, Belgium) using the
CB1R-selective ligand [18F]MK-9470 (Burns et al., 2007) to
confirm that selected doses achieved a similar level of CB1R oc-
cupancy in humans. Utilizing this technique, dose-dependent
CB1R occupancy was demonstrated (Figure 1A). Parametric
standardized uptake value (SUV) images demonstrated overall
homogeneous dose-dependent occupancy throughout the brain
approximately 24 hr after the last taranabant dose. There was
a good correlation between the level of CB1R occupancy
achieved and plasma levels of taranabant, calculated as the
average of plasma levels at the start and end of image acquisi-
tion, when plotted using the Hill equation and a Hill coefficient
(nH) of 1. As shown in Figure 1B, the plasma concentration oftaranabant required to achieve an average target CB1R brain
occupancy (Occ30) of 30% at 24 hr was 7 nM (3.6 ng/ml). This
level of brain CB1R occupancy was reached with taranabant
Figure 1. Brain Positron Emission Tomography Studies with
[18F]MK-9470
(A) Brain CB1R occupancy from a representative subject following taranabant
administration as assessed by [18F]MK-9470 positron emission tomography
(PET) illustrated by parametric standardized uptake value images acquired
before (top) and 24 hr after (bottom) the last dose following 14 days of daily
treatment with a 7.5 mg dose of taranabant. CB1R occupancy was homoge-
neous throughout the brain, andmean ± SD receptor occupancy in the studied
regions was 49% ± 3%. The left column shows a horizontal section through
the basal ganglia and thalamus, the middle column (coronal section) shows
cortical regions and thalamus, and the right column (sagittal section) shows
the uptake in cortical areas, cerebellum, and brain stem.
(B) Brain CB1R occupancy as assessed by PET imaging with [18F]MK-9470 as
a PET tracer following single or multiple doses of taranabant. A first-order Hill
curve (nH = 1) is fitted through all data.
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those that we have reported for taranabant using [18F]MK-9470
in rhesus monkeys with Occ30 = 9 nM (4.6 ng/ml) (Burns
et al., 2007).
12-Week Dose Range-Finding Weight-Loss Study
A multicenter, double-blind, placebo-controlled 12-week dose
range-finding weight-loss study was undertaken with a primary
hypothesis stating that taranabant would decrease body weight
in obese patients more than treatment with placebo in a dose-
related manner. Five hundred and thirty-three patients were
randomized, and 368 patients underwent body-weight measure-
ment after 12weeks of treatment (see Tables S1 and S2 available
online for categorical and continuous baseline patient character-
istics). The numbers and causes of early patient discontinuations
were generally similar across treatment groups (Table 1). There
was no significant trend in total patient discontinuation across
the five study groups, and discontinuations due to lack of effi-
cacy, withdrawal of consent, and clinical adverse events were
similar in placebo and taranabant groups.
Figure 2 and Table S3 summarize body weight loss in the
all patients treated (APT) population. Using the last observation
carried forward (LOCF) to impute missing data, the least-
squares (LS) mean changes from baseline were 1.2 and
2.9, 3.9, 4.1, and 5.3 kg for placebo and taranabant
0.5, 2, 4, and 6 mg, respectively. A significant trend over the en-
tire range of study doses was observed (p < 0.001). Using a lon-
gitudinal mixed-effects model, the LS mean changes from base-
line to week 12 were 1.4, 3.1, 3.9, 4.9, and 5.9 kg,
respectively. Results based on the per protocol completers pop-
ulation were consistent with findings from the APT population
(mean weight changes from baseline to week 12 were 1.4
and 3.6, 4.3, 5.2, and 6.3 kg for placebo and taranabant
0.5, 2, 4, and 6 mg, respectively). There was also a significant
Table 1. Overall Patient Disposition in the 12-Week
Weight-Loss Study
Placebo
Taranabant
0.5 mg 2 mg 4 mg 6 mg
Total patients (n) 105 106 109 105 108
Patients who completed
study
65 77 79 64 73
Patients who were
discontinueda
40 29 30 41 35
Clinical adverse event 11 5 5 17 11
Lack of efficacy 3 0 0 1 0
Protocol deviation 1 2 1 0 2
Patient uncooperative 0 0 0 0 1
Patient withdrew consent 8 9 8 7 4
Patient discontinued
for other reason
5 4 2 4 4
Patient moved 0 1 1 0 0
Patient lost
without follow-up
12 7 13 12 12
a Includes patients who discontinued drug with or without follow-up or
who discontinued at visit 10 during the treatment phase.
70 Cell Metabolism 7, 68–78, January 2008 ª2008 Elsevier Inc.dose-response trend in the change in waist circumference (see
Table S4).
Safety and Tolerability
The numbers (%) of patients who discontinued due to adverse
events (AEs) were 11 (10.5%) and 5 (4.7%), 5 (4.6%), 17
(16.2%), and 11 (10.2%) for placebo and taranabant 0.5, 2, 4
and 6 mg, respectively. Table S5 summarizes AEs that occurred
over the entire study period.
There were trends across dose in gastrointestinal (GI)-related
AEs (overall incidence in the body system, and the specific AEs
of nausea, frequent bowel movements or loose stools, and vom-
iting) (Table 2). The onset of GI-related AEs tended to be early
(Figure S1), but despite the high incidence, only 12 (4.8%) of
the 251 patients across all study groups who experienced
GI-related AEs discontinued the protocol.
A trend across doses for psychiatric-related AEs (overall
incidence in the body system, and the specific AE anxiety)
was observed (Table 2). The onset of psychiatric-related AEs
tended to be early (Figure S2), and 20 of 134 (15%) of patients
who experienced psychiatric-related AEs were discontinued
because of those AEs. There was no significant trend in the
incidences of AEs due to depressed mood/depressive symp-
toms, depression, insomnia, and irritability across the range
of doses (p > 0.2). No statistically significant intergroup differ-
ences were observed in the Patient Health Questionnaire-9
(Kroenke et al., 2001) depression questionnaire or the Profile
of Mood States (McNair et al., 1971) questionnaire.
An expanded listing of gastrointestinal and psychiatric AEs
occurring at a frequency R 2% by investigator-assigned drug
relatedness and organ system class is provided in Table S6.
Figure 2. Weight Changes Observed in the 12-Week Dose Range-
Finding Weight-Loss Study
Mean change in body weight (kg) over 12 weeks of treatment using last obser-
vation carried forward (LOCF) and repeated-measures analysis (RMA) (all
patients treated [APT] population). LSMeans (LOCF): estimates and 84% con-
fidence interval (CI) based on analysis of covariance (ANCOVA) model with
terms for treatment, baseline body weight, center, and run-in weight change.
RMA: estimates (84% CI) based on repeated-measures ANCOVA model with
terms for treatment, baseline body weight, center, run-in weight change,
weight by treatment, and weight by run-in weight change.
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Placebo
Taranabant
0.5 mg 2 mg 4 mg 6 mg
Total patients (n) 105 106 109 105 108
GI-related AEsa,b 40 (38.1%) 41 (38.7%) 48 (44.0%) 64 (61.0%)a 58 (53.7%)a
Diarrhea 7 (6.7%) 4 (3.8%) 8 (7.3%) 11 (10.5%) 8 (7.4%)
Nausea 7 (6.7%) 11 (10.4%) 20 (18.3%)a 33 (31.4%)a 33 (30.6%)a
Frequent bowel
movements, loose stools
10 (9.5%) 13 (12.3%) 12 (11.0%) 29 (27.6%)a 19 (17.6%)a
Vomiting 4 (3.8%) 3 (2.8%) 6 (5.5%) 10 (9.5%)a 15 (13.9%)a
Psychiatric-related AEs 19 (18.1%) 22 (20.8%) 30 (27.5%)b 33 (31.4%)a 30 (27.8%)a
Anxiety 3 (2.9%) 2 (1.9%) 3 (2.8%) 5 (4.8%) 11 (10.2%)a
Affect lability,
inappropriate affect, crying,
tearfulness, altered mood,
mood swings
4 (3.8%) 4 (3.8%) 3 (2.8%) 8 (7.6%) 9 (8.3%)b
Depressed mood
or depressive symptom
3 (2.9%) 5 (4.7%) 6 (5.5%) 7 (6.7%) 6 (5.6%)
Insomnia 5 (4.8%) 6 (5.7%) 9 (8.3%) 7 (6.7%) 6 (5.6%)
Irritability 2 (1.9%) 8 (7.5%) 8 (7.3%) 9 (8.6%) 3 (2.8%)
Nervousness 0 (0.0%) 2 (1.9%) 3 (2.8%) 3 (2.9%) 4 (3.7%)b
Tier 1 gastrointestinal (GI)- and psychiatric-related adverse events (AEs) for which inferential testing was performed. See Table S6 for expandedGI and
psychiatric AE listing.
a Trend test was significant between placebo and the corresponding taranabant dose (p < 0.050).
b Trend test was borderline significant between placebo and the corresponding taranabant dose (0.050 < p% 0.010).24-Hour Food Intake Study
A single-center (SGS Biopharma; Antwerp, Belgium), double-
blind, placebo- and active-controlled, single-dose, four-period
crossover study was conducted to assess the effect of tarana-
bant on reducing caloric intake over a 24 hr period. Thirty-six
overweight and moderately obese subjects participated in this
study. The doses of taranabant used in this study (4mg or 12mg)
were chosen in order to approximate steady-state exposure to
the dose range of taranabant (up to 6 mg) in the weight-loss
study (see Experimental Procedures).
Figure 3 and Table S7 summarize the food intake results. Of
primary interest was the reduction in 24 hr cumulative food
intake. Subjects randomized to taranabant 4 mg or 12 mg
demonstrated a total caloric intake over 24 hr of 4410 kcal and
3480 kcal, respectively, representing a 1% (p = 0.489) and 22%
(p < 0.001) reduction relative to placebo (4471 kcal) (Figure 3A
and Table S7). The active comparator sibutramine (30 mg) re-
duced 24 hr caloric intake to 3955 kcal, a 12% reduction relative
to placebo (p = 0.002).
During the initial postdose meal, ad libitum lunch, the mean
caloric intake was 1596, 1558, 1164, and 1273 kcal for placebo,
taranabant 4 mg, taranabant 12 mg, and sibutramine, respec-
tively, representing a 4% (p = 0.556), 27% (p < 0.001), and
20% (p < 0.001) reduction relative to placebo. This relative
food intake pattern was consistent across the other individual
meals, ad libitum dinner, evening snack, and next-day breakfast
(Figure 3A). No statistically significant differences were observed
in the intake of macronutrients (i.e., carbohydrate, fat, and
protein) when compared to one another over 24 hr or at individual
meals (Figure 3B; Table S8). All compounds administered were
well tolerated.Resting Energy Expenditure Study
A single-center (SGS Biopharma; Antwerp, Belgium), double-
blind, placebo- and active-controlled, single-dose, four-period
crossover study was conducted to assess the effect of tarana-
bant on resting energy expenditure (REE) over 5 hr following
dosing and at 24 hr postdose. As in the food intake study, the
doses in this study were intended to achieve exposure similar
to that in the 12 weeks of multiple-day 2 mg or 6 mg dosing of
taranabant. Seventeen overweight or moderately obese sub-
jects were enrolled in this study.
Figure 4A summarizes the change in energy expenditure
following single-dose administration as measured using indirect
calorimetry. The geometric mean ratio (GMR) of peak REE 2–5 hr
postdose is shown in Figure 4B. Compared to placebo, the GMR
of peak REE after treatment with 12 mg of taranabant and 30 mg
of sibutramine (95%confidence interval [CI]) versus placebowas
1.06 (1.01, 1.10) (p = 0.011) and 1.03 (0.99, 1.07) (p = 0.190),
respectively. The 12 mg dose of taranabant was associated
with a significant decrease in mean respiratory quotient (RQ)
over 0–5 hr postdose compared to placebo (LS GMR [95%
CI] = 0.97 [0.95, 1.00]; p = 0.023), suggesting increased fat
metabolism (Figure 4C). Change from baseline summary statis-
tics for REE and RQ data 0–5 hr postdose are presented in
Tables S9–S12. All compounds administered were generally
well tolerated, and there were no serious adverse experiences.
DISCUSSION
The PET study demonstrated in vivo occupancy of brain CB1R
after single- and multiple-dose administration of taranabant as
assessed by the selective CB1R ligand [18F]MK-9470. Moreover,
Cell Metabolism 7, 68–78, January 2008 ª2008 Elsevier Inc. 71
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the 12-week weight-loss efficacy study were associated with
brain CB1R occupancies of approximately 10%–40%, similar
to the range observed in preclinical weight-loss efficacy and
brain CB1R occupancy studies (Burns et al., 2007; Fong et al.,
2007).
The achieved levels of CB1R occupancy were associated with
significant weight loss across the full range of evaluated daily
doses of taranabant, 0.5 to 6 mg. Weight loss continued over
the 12-week study period, and the maximum weight loss attain-
able with the taranabant doses utilized in this study will need to
be determined in longer-duration studies. These observations
with taranabant extend earlier clinical observations with rimona-
bant (Van Gaal et al., 2005; Despres et al., 2005; Pi-Sunyer et al.,
2006; Scheen et al., 2006), although efficacy comparisons are
not possible without appropriately designed head-to-head
studies.
Figure 3. 24-Hour Food Intake Effects
(A) Twenty-four hour andmeal-specific caloric intake (kcal) after administration
of single doses of placebo, 4 or 12 mg taranabant, or 30 mg sibutramine.
* denotes statistical significance versus placebo at p levels enumerated in
Table S7. Error bars represent SEM.
(B) Macronutrient caloric intake relative to placebo (geometric mean ratio) after
administration of single doses of 4 mg taranabant, 12 mg taranabant, or 30 mg
sibutramine. Error bars represent 95% CI.
72 Cell Metabolism 7, 68–78, January 2008 ª2008 Elsevier Inc.GI-related AEs were the most frequent AEs observed in the
12-week dose range-finding weight-loss study and are likely to
bemechanism based. CB1Rs are expressed by enteric neurons,
and their activation reduces GImotility (Coutts and Izzo, 2004). In
addition, CB1Rs have been found in areas of the hindbrain
involved in emesis (Coutts and Izzo, 2004). In rodent studies,
rimonabant has been shown to be prokinetic, although tolerance
to this effect reportedly develops rapidly (Carai et al., 2004). This
latter observation is in general agreement with our human data in
that GI-related AEs tended to occur early in the 12-week study.
Nausea and emesis have also been reported in the published
rimonabant studies (Van Gaal et al., 2005; Despres et al., 2005;
Pi-Sunyer et al., 2006; Scheen et al., 2006), which suggests
this may be a mechanism-based AE category.
CB1Rs are present throughout other areas of the brain in
addition to the hypothalamus, and there is clinical concern for
potential psychiatric-related AEs (Gadde and Allison, 2006).
The occurrence of psychiatric-related AEs in the 12-week study
in conjunction with the data reported in the published rimona-
bant studies (Van Gaal et al., 2005; Despres et al., 2005;
Pi-Sunyer et al., 2006; Scheen et al., 2006) suggests that these
AEs may also be mechanism based and inherent to brain-pene-
trant CB1R inverse agonists. Although understanding of the neu-
roanatomical pathways involved in mood regulation is limited,
research implicates a distributed system that is extensively inter-
connected (Soares andMann, 1997; Byrum et al., 1999; Semino-
wicz et al., 2004). According to one model, two main brain
circuits involved in this process are the limbic-thalamic-cortical
circuit and the limbic-striatal-pallidal-thalamic-cortical circuit
(Soares and Mann, 1997). Data from our PET imaging study indi-
cate that CB1Rs are expressed at high levels in the limbic system
and prefrontal cortex. It is conceivable that drug-induced
changes in the modulator function of CB1R in one or more of
these brain areas could produce varying degrees and types of
mood dysfunction.
The factors that predispose some people to mood alterations
with CB1R inverse agonists remain to be elucidated. Although
data from the present study appear to indicate that psychiat-
ric-related AEs are manageable at the doses of taranabant
utilized, larger and longer-duration studies will be needed to
obtain a more accurate assessment of the psychiatric profile of
taranabant. Because psychiatric-related AEs are presumably
due to brain CB1R occupancy, [18F]MK-9470 PET studies may
prove to be a valuable pharmacodynamic tool for the future
development of such compounds. As demonstrated in the cur-
rent study, weight-loss efficacy does not require 100% CB1R
occupancy; thus, 0.5 to 6 mg taranabant treatment is not
expected to completely eliminate endocannabinoid signaling
and thus is not equivalent to CB1R knockout in mice.
The food intake and REE studies are an important extension of
rodent studies (Ravinet Trillou et al., 2003; Liu et al., 2005; Herling
et al., 2007) and suggest that the clinical weight loss induced by
taranabant is secondary to both decreases in food intake and
increases in energy expenditure. Our clinical trial demonstrates
that changes in REE may occur as a result of inverse agonism
of the CB1R. Single-dose administration of taranabant 12 mg,
which simulates steady-state exposure to a 6 mg chronic
dose, caused a small but clearly detectable increase in REE
and fat oxidation. Such modest increases in energy expenditure,
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Effects Postdose
(A) Changes in resting energy expenditure (REE) (kcal/day) 0–5 hr postdose
(mean ± SEM).
(B) Peak REE relative to placebo (geometric mean ratio) following single doses
of 4 mg taranabant, 12 mg taranabant, or 30 mg sibutramine. Error bars rep-
resent 95% CI.particularly when combined with appetite suppression, could
exert profound effects on body weight over a period of months.
The lack of detectable effects of the single 4 mg dose of tara-
nabant, which simulates steady-state exposure to a 2 mg
chronic dose, and the effects observed with sibutramine on
REE are likely due to the limits of detection of current methodol-
ogies (Clapham, 2004). In this regard, increases in energy expen-
diture have been noted in some, but not all, sibutramine studies
(Hansen et al., 1998, 1999; Seagle et al., 1998; Walsh et al.,
1999), although prevention of a decline in energy expenditure
following weight loss has been proposed as another mechanism
bywhichminimal changes in REE could contribute to weight loss
over time (Astrup et al., 1999; Wyatt et al., 1999). It remains to be
established what proportion of taranabant’s effects on REE are
mediated centrally via activation of the autonomic nervous
system or peripherally by engagement of CB1R expressed by
the peripheral tissues.
The results of the single-dose food intake study are consistent
with the well-documented food intake inhibition effects of CB1R
inverse agonists in rodents. Rodent studies have demonstrated
that despite the development of partial tachyphylaxis, a
10%–25% reduction in steady-state food intake is nonetheless
maintained after repeated dosing of rimonabant or taranabant
(Ravinet Trillou et al., 2003; Fong et al., 2007). The lack of statis-
tically significant inhibition of food intake by the 4 mg dose of
taranabant, which mimics a 2 mg chronic dose, in the acute
food intake study may also represent a limitation of our evalua-
tion methods. Nonetheless, the 4 mg dose did produce a small
inhibition of food intake directionally similar to the 12 mg dose.
The current study further demonstrates that the reduction
in food intake is distributed equally across macronutrients
(Figure 3B), consistent with rodent studies in which rimonabant
inhibited the intake of both sweet foods and bland chow (Freed-
land et al., 2000; Perio et al., 2001; Rowland et al., 2001).
Several limitations of these studies should be considered.
First, brain CB1R occupancy was evaluated only in lean male
subjects, and the extent to which these data can be extrapolated
to obese females, who are likely to comprise a significant propor-
tion of the treatment population, needs to be confirmed. The tar-
geted CB1R occupancy in this study was based on available
multiple-dose pharmacokinetic data and extrapolations to the
plasma concentration/CB1R occupancy relationship that had
been previously observed in preclinical studies. At the point in
time that this study was conducted, preclinical safety studies
had not been completed to support multiple-dose administration
of taranabant in women, and therefore multiple-dose pharmaco-
kinetic data were available only in lean male subjects. Taking
these considerations together, the decision was made to con-
duct the CB1R occupancy study in lean male subjects. It is pos-
sible that CB1R occupancy rates or density may differ in obese
individuals compared to lean individuals and in women com-
pared to men, although current data suggest that occupancy is
independent of receptor density (Burns et al., 2007). Second,
food intake was evaluated only after single-dose administration,
and the degree to which suppression of food intake wanes in hu-
mans with chronic dosing, as observed in rodent studies, needs
(C) Changes in respiratory quotient (RQ) from baseline 0–5 hr postdose (mean
± SEM).
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examine REE atmultiple time points to observewhether changes
occur over time. The final concern, one common tomost weight-
loss drug trials, is the high and similar intergroup dropout rate
observed over the 12-week evaluation period; however, the
results were consistent among different methods for handling
missing data and between the intention to treat and per protocol
completers populations.
The contribution of reductions in food intake and increase in
energy expenditure to overall weight loss on a chronic basis
remains to be determined.
EXPERIMENTAL PROCEDURES
Brain CB1R Occupancy Study
Study Design
This was a randomized, double-blind, placebo-controlled study (Merck proto-
col 008) in which 15 healthy, nonsmoking male subjects, with mean age of 29.7
years (range 19 to 43) and mean body weight of 76.4 kg (range 63.6 to 93.7)
were randomized to receive one of five 14-day multiple-dose treatments: pla-
cebo, taranabant 1 mg, taranabant 4 mg, taranabant 7.5 mg, or single-dose
taranabant 12 mg followed by daily single-dose administration of taranabant
6 mg for at least 13 days.
The dose ranges selected for evaluation in this study were based upon
projected brain CB1R occupancy, which was extrapolated from preliminary
plasma concentrations following multiple-dose taranabant administration in
human subjects and the relationship between brain CB1R occupancy and
steady-state taranabant concentration in preclinical studies. Evaluation of
CB1R occupancy following a single 12 mg dose, which was predicted to
approximate steady-state plasma concentrations for the 6mg dose, permitted
exploration of the relationship of plasma concentration and brain CB1R occu-
pancy following single-dose administration and whether this relationship is
similar to that following multiple-dose administration.
Patientswere grouped into four panels: the first panel randomized 6patients,
2 each to 1 mg taranabant, 7.5 mg taranabant, and placebo; the second panel
randomized 3 patients, 2 patients to 4 mg taranabant and 1 to placebo; the
third panel randomized 3 patients, 2 patients to 7.5mg taranabant and 1 to pla-
cebo. The fourth panel was conducted open-label, with all patients receiving
a single dose of 12 mg taranabant followed by 13 days of 6 mg taranabant.
Doses for the second, third, and fourth panels were chosen after evaluation
of the data in the preceding panels. A computer-generated allocation schedule
was utilized in the allocation of patients to the treatments. Patients, investiga-
tors, and sponsor staff were blinded to the treatment assignment in the first
three panels; blind was maintained at the site through the use of matching
placebo capsules.
All subjects underwent a baseline [18F]MK-9470 PET scan on day 1 following
an overnight fast. Following the baseline PET scan, subjects were adminis-
tered a single oral taranabant dose (1 mg, n = 2; 4 mg, n = 3; 7.5 mg, n = 4)
or placebo (n = 3) once daily for 13 days. On day 14, at approximately
23–24 hr following the day 13 dose and following an overnight fast, a second
[18F]MK-9470 PET scan was initiated. One panel of subjects was administered
a single dose of taranabant 12 mg on day 1, followed by once-daily dosing of
taranabant 6 mg for 14 days (n = 2) or 17 days (n = 1). [18F]MK-9470 PET scans
were initiated at approximately 23 hr following day 1 and day 14 (or day 17)
dosing. Blood samples were taken from all subjects at specified times pre-
and post-taranabant/placebo dosing for assessment of taranabant plasma
concentration.
[18F]MK-9470 synthesis was performed at the PET site as described previ-
ously (Burns et al., 2007). The HPLC-purified final product had a radiochemical
purity > 95%. Specific activity was higher than 10 gigabecquerels (GBq)/mmol
at time of injection, and the mass of MK-9470 administered to each subject
during the study did not exceed 27 mg. PET acquisitions were performed as
described previously (Burns et al., 2007). Per scan, subjects received an aver-
age (±SD) of 170.0 ± 14.0 megabecquerels (MBq) [18F]MK-9470 in slow i.v.
injection. The scanning protocol for all subjects in this study consisted of
0–90 min and 120–180 min dynamic scans. Pilot dosimetry studies have
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2.3 millisieverts.
Safety and tolerability were assessed throughout the study by monitoring
clinical AEs; physical examinations including neurological examinations, vital
signs, 12-lead ECG, and laboratory safety tests (CBC, serum chemistry, urinal-
ysis); and visual analog scale questionnaire assessments of mood/alertness.
Statistical Methods and Analysis
The primary objective of the study was to estimate the dose-response
relationship between plasma concentrations of taranabant and PET receptor
occupancy.
CB1R availability for occupancy estimation was based on the shape of the
time-activity curves (TACs) (Koeppe et al., 1999). A tracer validation study
demonstrated that [18F]MK-9470 brain activity concentration is stable
from 120 min to up to 6 hr after tracer injection, while the [18F]MK-9470 plasma
concentration becomes negligible. Therefore, the area under the tissue TAC
in the 120–180 min interval, or AUC120–180 min, was used as an index of
CB1R occupancy. In order to compare CB1R occupancy under baseline
(BL) conditions and after taranabant dosing (PD), the measured tissue TACs
(in Bq/cc) were expressed as a standardized uptake value (SUV) using each
subject’s weight and the corresponding tracer-injected dose, TAC(SUV) =
TAC(Bq/cc) 3 1000 3 weight (kg)/injected dose (Bq). CB1R occupancy was
then calculated using AUC120–180 min as 100 3 (1 – AUC (PD)/AUC (BL)).
Brain CB1R occupancy after administration of multiple oral doses of tarana-
bant was explored through nonlinear modeling of receptor occupancy mea-
sures versus day 14 taranabant trough plasma concentrations. Taranabant
plasma concentration data were common log transformed prior to the analy-
sis. The brain receptor occupancy data were fit with a curve described by
a Hill equation: occupancy (%) = A ynH/((Occ50)
nH + ynH), where y corresponds
to taranabant plasma concentration, A was set to 100% (maximum
occupancy), and the Hill coefficient nH was set to 1. The study was not pow-
ered to detect a specific difference between treatment groups, but rather to
provide information on the dose-response relationship. The numbers of
patients per dose were chosen based on previous PET imaging studies
(Erondu et al., 2006).
12-Week Dose Range-Finding Weight-Loss Study
Study Design
This was a multicenter, double-blind, placebo-controlled study (Merck proto-
col 006, NCT00109148). Patients with a body mass index (BMI) R 30 kg/m2
and% 43 kg/m2, between the ages of 21 and 65 years, who had no significant
organ system dysfunction (CNS, cardiac, pulmonary, renal, diabetes mellitus,
etc.) as assessed by routine laboratory values and investigator evaluation were
eligible to participate. Prior to randomization, there was a 2-week single-blind
placebo run-in period. Patients were assigned to one of five treatments (plus
dietary/exercise counseling): placebo or one of four doses of taranabant.
Each group was treated for a period of 12 weeks followed by 6 weeks of off-
drug safety follow-up. From visit 1 (week 2) through the end of the trial,
patients were instructed by a dietitian to follow a diet that was 500 kcal below
calculated weight maintenance requirements. Body weight, waist circumfer-
ence, assessment of appetite/satiety, patient-reported outcomes by question-
naires, blood pressure, ECG, hematology, serum chemistry, urinalysis, fasting
plasma lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, non-
HDL cholesterol, triglycerides), fasting plasma glucose, and insulin levels
were collected at multiple time points. Assessments of psychological status,
mood, and cognitive function using the Patient Health Questionnaire-9
(PHQ-9) (Kroenke et al., 2001), Profile of Mood States (McNair et al., 1971),
and Digit Symbol Substitution Test (Wechsler, 1997) questionnaires, respec-
tively, were also performed.
Patients with active psychiatric disorders or a history of psychiatric disorder,
including but not limited to major depression, bipolar disorder, schizophrenia,
or other psychiatric disorders, history of attempted suicide, or suicidal idea-
tion, were excluded from the study. The PHQ-9 was administered at screening
and randomization (baseline) to identify and exclude subjects with clinically
significant depression. At screening and baseline, a score > 12 on the PHQ-
9 or > 0 on question 9 (which probes for suicidal ideation) was exclusionary.
Patients were randomized to the five treatment groups using a computer-
generated allocation schedule. Patients, investigators, and sponsor staff
were blinded to the treatment assignments until the planned interim analysis;
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tained through the use of matching placebo capsules and coded bottles; the
same matching placebo capsules were used in the 2-week run-in as were
used in the double-blind period. An interactive voice response system was
used to allocate treatment assignments and study medication.
Statistical Methods and Analysis
The primary hypotheses of the study were that (1) 12 weeks of treatment with
taranabant decreases body weight more than treatment with placebo in
a dose-related manner in obese patients and (2) daily administration of tarana-
bant for 12 weeks is safe and well tolerated in obese patients. The secondary
hypothesis was that the proportion of obese patients whose body weight
decreases by at least 5% from their baseline body weight is greater after
12 weeks of treatment with taranabant than after treatment with placebo.
The primary analysis population was the all patients treated (APT) popula-
tion, defined as randomized patients who received at least one dose of study
medication and who had at least one postbaselinemeasurement. A secondary
analysis population was the per protocol completers population, which was
defined as those patients who were on drug for 12 weeks without major
protocol deviations.
The primary efficacy variable, change from baseline (week 0) in body weight
after 12 weeks of treatment, was assessed using an analysis of covariance
(ANCOVA) model with terms for study center, baseline body weight, and
weight change during the 2-week run-in period and treatment. Comparisons
of doses of taranabant to placebo were conducted using a step-down trend
test. The proportions of patients whose body weight decreased by at least
5% or by at least 10% from their baseline body weight after 12 weeks of treat-
ment were evaluated by a logistic regression model with factors for treatment,
baseline body weight, and weight change during the 2-week run-in period and
treatment. Safety and tolerability of taranabant were assessed by clinical and/
or statistical assessment of all relevant safety data, including adverse experi-
ences, laboratory values, mood and cognitive function, and ECG data. An ad-
ministrative interim analysis for efficacy was performed after most patients had
been scheduled to complete 8 weeks of treatment. The results of this interim
analysis were used to plan other studies and did not alter the design or conduct
of the study; thus, a penalty reduction of 0.001 in the a level (type I error) was
applied to the interim analysis on the primary endpoint of body weight; final
study results were assessed at an a level of 0.049. The study planned to enroll
100 patients per treatment group. Assuming an intergroup standard deviation
of 2.64 kg (Erondu et al., 2006), this study had 90% (80%) power to detect a
difference of 1.22 kg (1.06 kg) in themean change from baseline in body weight
between any two treatment groups.
24-Hour Food Intake Study
Study Design
Thirty-six overweight and moderately obese (BMI 25–35 kg/m2), otherwise
healthy nonsmoking male subjects with mean age 38.6 years (range
21 to 45) and mean weight 98.4 kg (range 79.0 to 116.6) were randomized
(Merck protocol 016) in order to have 32 subjects complete all four periods.
All patients were administered single oral doses of 4 mg or 12 mg taranabant,
30 mg sibutramine, or placebo capsules in a crossover fashion. The doses of
taranabant and sibutramine were chosen to replicate steady-state plasma
concentrations, assuming an accumulation ratio of 2 with multiple dosing
(e.g., the 12 mg dose was designed to replicate steady-state exposure to
6 mg). A single 30 mg dose of sibutramine was chosen since this dose is as-
sociated with robust chronic weight loss approaching 10% over 6 months
(see sibutramine package insert) that would be highly desirable in a new ther-
apeutic agent for obesity.
In each treatment period, subjects were admitted to a clinical research
center the evening prior to dosing and completely consumed a standardized
dinner at 7 p.m. Following a 13 hr overnight fast, subjects were then admin-
istered study drug. Thirty minutes after dosing, subjects were required to
completely consume a fixed-quantity breakfast of 200 kcal. Subjects then
fasted, except that small quantities of water were permitted, until the ad libitum
lunch meal 3 hr postdose (approximate Tmax of taranabant). Food items for the
lunch meal were provided in excess (5-fold over standard portions), and
subjects were instructed to eat as much or as little as desired.
An ad libitum dinner meal, evening snack, and breakfast were also provided
at 10, 14, and 24 hr postdose to allow for an assessment of food intakeover 24 hr. All food items (including serving items, i.e., utensils, plates, etc.)
were covertly weighed before and after consumption in accordance with
study-specific procedures. The before-and-after weighing allowed measure-
ment of serving items to within 0.1 g, and nutrient analysis was performed
for each ad libitummeal. Subjects were informed that the purpose of the study
was to measure the effects of taranabant or sibutramine on hunger, eating
behavior, and other physiologic measures such as heart rate and blood pres-
sure. Subjects consumed all meals alone in a private room. During meal times,
leisure activities such as reading, watching videos, and listening to music were
not permitted, and social and time cues (e.g., clocks, radios, cell phones, tele-
visions) were removed. Subjects were not disturbed for up to 2 hr during each
test meal but were allowed to ambulate freely outside rooms upon finishing
each meal to their satisfaction. Each testing period was separated by at least
a 3-week washout period.
Evaluation of the subjects’ regular eating behavior was obtained via ques-
tionnaire, and abnormal eating patterns and food preference or dieting were
criteria for exclusion. Questionnaires included the three-factor Eating Inven-
tory (EI) (Stunkard and Messick, 1988), the Eating Attitudes Test-26 (EAT-26)
(Garner et al., 1982), and a food preferences rating scale (listing the foods
included in each study meal). A duplicate ad libitum lunch meal was provided
at screening to reduce the ‘‘first test day’’ effect observed in food intake stud-
ies, to familiarize subjects with the meal procedures, and to identify any
extreme behaviors or aversive reactions to test meal items. The protocol
included collection of vital signs, a physical and neurological examination,
safety laboratories, and an ECG. Subjects were assessed for adverse events.
Patients were randomized to the four sequences of treatment group assign-
ments using a computer-generated allocation schedule. Patients, investiga-
tors, and sponsor staff were blinded to the treatment assignments; blind at
the site was maintained through the use of matching placebo capsules and
coded bottles.
Statistical Methods and Analysis
The primary hypotheses of the study were that (1) one or both single doses of
taranabant reduce 24 hr caloric intake following administration of ad libitum
test meals in overweight and obese male volunteers relative to placebo
(a 10% or greater reduction in caloric intake compared to placebo was
expected) and (2) both single doses of taranabant are generally well tolerated.
The caloric intake data were analyzed with an ANOVA appropriate for a four-
period crossover design. The ANOVA model contained three factors: subject,
period, and treatment. A test for first-order carryover effect was performed,
and no significant carryover was found. A log transformation was applied to
the caloric intake data. Back-transformed summary statistics, 95% CIs for
intratreatment geometric mean and intertreatment GMR (e.g., taranabant/pla-
cebo), and p values were derived from the ANOVAmodel for all treatments and
treatment comparisons. To account for the multiple-dose comparisons, the
doses were assessed sequentially: the high dose of taranabant was tested
first, and if it significantly decreased food intake, then the low dose of tarana-
bant was evaluated. Tests were conducted at a = 0.05. With 32 subjects, this
study had 80% power to detect a significant effect if the true reduction in food
intake was 10% over 24 hr and >99% power to detect a difference if the true
reduction in food intake was 20%.
Resting Energy Expenditure Study
Study Design
Seventeen overweight and moderately obese (BMI 25–35 kg/m2), otherwise
healthy nonsmoking male subjects, with mean age 39.1 years (range
31 to 45) and mean body weight of 91.4 kg (range 76.0 to 104.8) were random-
ized (Merck protocol 033) to a sequence of four single-dose treatments (pla-
cebo, 4 mg taranabant, 12 mg taranabant, 30 mg sibutramine) with at least
21 days between dosing in consecutive periods.
In each treatment period, subjects were admitted to the clinical research unit
(CRU) on the day prior to dosing and received a standardized evening meal.
Following a 13 hr overnight fast, subjects were administered study drug in
double-blind, double-dummy fashion and continued to fast through comple-
tion of the 5 hr postdose indirect calorimetry procedures (Vmax Encore, Sen-
sorMedics). Subjects were permitted to listen to music to facilitate relaxation
and wakefulness through the 5 hr postdose procedures. All efforts were
made by CRU staff to minimize noise, distractions, and interruptions. Subjects
received a standardized lunch (immediately following the 5 hr postdose
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sumed on the evening prior to dosing. Following a 13 hr overnight fast, sub-
jects had indirect calorimetry procedures performed on day 2 at 24 hr post-
dose. Subjects were counseled regarding dietary intake, exercise, and the
importance of maintaining a stable weight between dosing periods.
Subjects were randomized to the four sequences of treatment group assign-
ments using a computer-generated allocation schedule. Patients, investiga-
tors, and sponsor staff were blinded to the treatment assignments; blind at
the site was maintained through the use of matching placebo capsules and
coded bottles.
Statistical Methods and Analysis
The primary hypothesis for the study was that taranabant increases peak REE
over 2–5 hr postdose relative to placebo; a true GMR of R1.04 was antici-
pated.
The peak REE was calculated as the maximum of the averages of two con-
secutive 30 min measurements within the 2–5 hr postdose time period. Peak
REE was analyzed using an ANOVAmodel appropriate for a four-period cross-
over design. The ANOVA model contained four factors: subject, baseline
energy expenditure, period, and treatment. A test for first-order carryover
effect was performed, and no significant carryover was found. A log transfor-
mation was applied to the peak REE data. The 30 min predose baseline REE,
the average of the two 30 min readings, and BMI were also examined as pos-
sible covariates for inclusion into the above ANOVA model. Back-transformed
summary statistics, 95%CIs for intratreatment geometric mean and intertreat-
ment GMR (e.g., taranabant/placebo), and p values were derived from the
ANOVA model for all treatments and treatment comparisons. To account for
the multiple-dose comparisons, the doses were assessed sequentially: the
high dose of taranabant was tested first, and if it significantly increased energy
expenditure, then the low dose of taranabant was evaluated. Tests were con-
ducted at a = 0.05. With 12 subjects, this study had 86% power to detect a
significant effect if the true mean ratio was 1.04, assuming an intrasubject
coefficient of variation of 3.46% based on Hansen et al. (1998, 1999).
All studies were approved by central or local institutional review boards or
ethical review committees and were conducted in accordance with the Inter-
national Conference on Harmonisation (ICH) guidelines on Good Clinical Prac-
tice and ethical standards for human experimentation established by the
Declaration of Helsinki. Each patient gave written informed consent. In the
PET, food intake, and energy expenditure studies, subjects received a stipend
for their participation in the study. Each study enrolled unique subjects/
patients; subjects were not reused in multiple studies.
Supplemental Data
Supplemental Data include Supplemental Results and Discussion, Supple-
mental References, Author Contributions, twelve tables, and two figures and
can be found with this article online at http://www.cellmetabolism.org/cgi/
content/full/7/1/68/DC1/.
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